Biomedicines (Nov 2022)

Adenosine and Adenosine Receptors: Advances in Atrial Fibrillation

  • Baptiste Maille,
  • Nathalie Lalevée,
  • Marion Marlinge,
  • Juliette Vahdat,
  • Giovanna Mottola,
  • Clara Degioanni,
  • Lucille De Maria,
  • Victor Klein,
  • Franck Thuny,
  • Frédéric Franceschi,
  • Jean-Claude Deharo,
  • Régis Guieu,
  • Julien Fromonot

DOI
https://doi.org/10.3390/biomedicines10112963
Journal volume & issue
Vol. 10, no. 11
p. 2963

Abstract

Read online

Atrial fibrillation (AF) is the most common arrhythmia in the world. Because the key to developing innovative therapies that limit the onset and the progression of AF is to fully understand the underlying molecular mechanisms of AF, the aim of the present narrative review is to report the most recent advances in the potential role of the adenosinergic system in the pathophysiology of AF. After a comprehensive approach describing adenosinergic system signaling and the mechanisms of the initiation and maintenance of AF, we address the interactions of the adenosinergic system’s signaling with AF. Indeed, adenosine release can activate four G-coupled membrane receptors, named A1, A2A, A2B and A3. Activation of the A2A receptors can promote the occurrence of delayed depolarization, while activation of the A1 receptors can shorten the action potential’s duration and induce the resting membrane’s potential hyperpolarization, which promote pulmonary vein firing, stabilize the AF rotors and allow for functional reentry. Moreover, the A2B receptors have been associated with atrial fibrosis homeostasis. Finally, the adenosinergic system can modulate the autonomous nervous system and is associated with AF risk factors. A question remains regarding adenosine release and the adenosine receptors’ activation and whether this would be a cause or consequence of AF.

Keywords